Compare Abeona Therapeutics Inc (ABEO) vs H2O America (HTO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs H2O America — how do they compare? Abeona Therapeutics Inc trades at $6.67 (market cap $373.32M), while H2O America trades at $61.66 (market cap $2.58B). The key difference: H2O America is far larger — about 6.9× Abeona Therapeutics Inc's market cap, and H2O America pays a 2.85% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | HTO | |
|---|---|---|
Market Cap | $373.32M | $2.58B |
Sector | Health | Technology |
52-Week High | $7.23 | $62.42 |
52-Week Low | $4.17 | $44.44 |
Enterprise Value | $228.22M | $4.31B |
Dividend Yield | — | 2.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
HTO trades at $61.21, down 1.94% on the day, with a bullish technical outlook supported by moving averages and a consensus price target of $61.33. The company reported Q1 2026 EPS of $0.50, beating expectations, and maintains strong fundamentals with a 12.87% net income margin. Recent news highlights executive appointments and institutional investments, reinforcing positive sentiment.
The stock presents a balanced opportunity with steady earnings growth and a reliable dividend, but faces risks from high RSI levels indicating overbought conditions and substantial capital expenditures. Analyst consensus is strongly bullish with 80% buy ratings, though investors should monitor execution of growth initiatives and sector-specific headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About H2O America
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →
